Ensysce Biosciences, Inc.
ENSC
$2.09
-$0.045-2.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1.23% | -61.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.23% | -61.87% | |||
| Cost of Revenue | -50.42% | 124.91% | |||
| Gross Profit | 77.36% | -244.60% | |||
| SG&A Expenses | 30.10% | -0.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.64% | 75.92% | |||
| Operating Income | 44.99% | -654.75% | |||
| Income Before Tax | 45.42% | -638.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 45.42% | -638.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 45.42% | -638.59% | |||
| EBIT | 44.99% | -654.75% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 52.12% | -388.93% | |||
| Normalized Basic EPS | 52.12% | -388.94% | |||
| EPS Diluted | 52.12% | -388.93% | |||
| Normalized Diluted EPS | 52.12% | -388.94% | |||
| Average Basic Shares Outstanding | 13.99% | 86.40% | |||
| Average Diluted Shares Outstanding | 13.99% | 86.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||